Research uncovers promising findings about an anti-aging drug for canines potentially extending their lifespans
In a groundbreaking development, the biotech company Loyal is set to release LOY-002, an anti-aging pill for senior dogs, by the end of 2025. This drug, designed to target age-related metabolic changes such as insulin resistance, is expected to be affordable, costing less than $100 per month[1][4].
Another promising compound for dogs is Nicotinamide Mononucleotide (NMN), which has shown potential in slowing aging, improving mobility, and enhancing the quality of life in senior dogs. In mouse studies, NMN extended lifespan by about 29%. NMN is also believed to help prevent and treat common age-related diseases in dogs such as heart, kidney, liver diseases, and diabetes[2].
For healthy aging support, multivitamins like those from Arterra Pet Science incorporate ingredients such as L-Taurine, Milk Thistle Seed Oil, and Coenzyme Q-10, aiming to promote heart health, liver protection, joint health, and overall wellness[3].
The potential impact on human aging is promising, as compounds like NMN target cellular pathways implicated in aging. NMN, a precursor to NAD+ (a critical coenzyme in cellular energy metabolism), shows potential in both animal models and early human studies for promoting longevity and mitigating age-related decline[1][2].
Research on drugs like LOY-002, developed specifically for dogs, also target metabolic pathways relevant in human aging, implying potential insights for human applications, although not yet confirmed in clinical trials for humans[1][2].
The latest success story comes from Donte's Den, a non-profit in Myakka City, Florida, where a 12-year-old German Shepherd named Zeus was diagnosed with terminal cancer. Enrolled in an age-reversal clinical trial, Zeus was given one pill a day. Within a week, Panuce, the dog's caretaker, observed significant improvement, with cancer disappearing from a recent scan[5]. Another dog, a 12-year-old Newfoundland named Benson, who was nearly incapacitated by severe arthritis, also showed improvement after taking the pill[5].
These developments represent important steps in understanding and potentially controlling aging across species. While no definitive human-age-reversal pills have emerged from these findings, they offer hope for the future of geriatric care for both dogs and humans. As Dr. Michael Roizen put it, "I'm not a scientist...but I think anything that we can have that will take a very dire situation and turn it around, I'm all for it."[5]
[1] https://www.reuters.com/business/healthcare-pharmaceuticals/biotech-companies-develop-age-reversal-drugs-for-dogs-2022-09-09/ [2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366583/ [3] https://www.arterrapetscience.com/products/ [4] https://www.loyal.com/press-releases/press-release-details/2022/Loyal-Announces-Clinical-Trial-Results-for-LOY-002-in-Dogs/ [5] https://www.cbsnews.com/florida/news/age-reversal-pill-for-dogs-extends-life-for-terminally-ill-senior-dog-at-florida-rescue-center/
- The biotech company Loyal is developing an anti-aging pill, LOY-002, for senior dogs, which targets age-related metabolic changes like insulin resistance and costs less than $100 per month.
- Another compound, Nicotinamide Mononucleotide (NMN), shows potential in slowing canine aging, improving mobility, and enhancing the quality of life in senior dogs.
- Multivitamins from Arterra Pet Science, containing ingredients like L-Taurine, Milk Thistle Seed Oil, and Coenzyme Q-10, support healthy aging in pets by promoting heart health, liver protection, joint health, and overall wellness.
- The human impact of compounds like NMN, which target cellular pathways implicated in aging, is promising, as they show potential in promoting longevity and mitigating age-related decline in both animal models and early human studies.
- Research on drugs like LOY-002, developed specifically for dogs, also targets metabolic pathways relevant in human aging, suggesting potential insights for human applications, although not yet confirmed in human clinical trials.
- In a non-profit rescue center, a 12-year-old German Shepherd named Zeus diagnosed with terminal cancer was given an age-reversal clinical trial pill and showed significant improvement within a week, with cancer disappearing from a recent scan, while a 12-year-old Newfoundland named Benson with severe arthritis also demonstrated improvement. These developments offer hope for the future of geriatric care for both dogs and humans.
